Efficacy of CLARA in recurrent/refractory acute myeloid leukaemia patients unresponsive to FLAG chemotherapy

Basit Öğe Kaydı
dc.contributor.authorKaya, Ali Hakan
dc.contributor.authorTekgunduz, Emre
dc.contributor.authorIlkkilic, Kadir
dc.contributor.authorDal, Mehmet Sinan
dc.contributor.authorMerdin, Alparslan
dc.contributor.authorKarakus, Abdullah
dc.contributor.authorHacioglu, Sibel Kabukcu
dc.date.accessioned2024-04-24T16:25:00Z
dc.date.available2024-04-24T16:25:00Z
dc.date.issued2018
dc.departmentDicle Üniversitesien_US
dc.description.abstractWe hereby report our multicentre, retrospective experience with CLARA in patients with fludarabine/cytarabine/GCSF (FLAG) refractory AML. The study included all consecutive R/R AML patients, who received CLARA salvage during October 2010-October 2015 period. All patients were unresponsive to FLAG salvage chemotherapy regimen and did not undergo previous allo-HCT. A total of 40 patients were included. Following CLARA 5 (12.5%) patients experienced induction mortality and 10 (25%) patients achieved CR. 25 (62.5%) patients were unresponsive to CLARA. 7 (17.5%) out of 10 patients in CR received allo-HCT. Median overall survival of patients who achieved CR after CLARA was 24.5 months (8.5-54.5) and 3 months (2.5-5), in patients who underwent and didn't allo-HCT, respectively. Our results indicate that CLARA may be good alternative even in FLAG refractory AML patients and can be used as a bridge to allo-HCT, who have a suitable donor and able to tolerate the procedure.en_US
dc.identifier.doi10.1080/1120009X.2017.1396017
dc.identifier.endpage48en_US
dc.identifier.issn1120-009X
dc.identifier.issn1973-9478
dc.identifier.issue1en_US
dc.identifier.pmid29098953
dc.identifier.scopus2-s2.0-85032801421
dc.identifier.scopusqualityQ3
dc.identifier.startpage44en_US
dc.identifier.urihttps://doi.org/10.1080/1120009X.2017.1396017
dc.identifier.urihttps://hdl.handle.net/11468/16924
dc.identifier.volume30en_US
dc.identifier.wosWOS:000428154600006
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherTaylor & Francis Ltden_US
dc.relation.ispartofJournal of Chemotherapy
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAcute Myeloid Leukaemiaen_US
dc.subjectAmlen_US
dc.subjectRelapseen_US
dc.subjectRefractoryen_US
dc.subjectClofarabineen_US
dc.titleEfficacy of CLARA in recurrent/refractory acute myeloid leukaemia patients unresponsive to FLAG chemotherapyen_US
dc.titleEfficacy of CLARA in recurrent/refractory acute myeloid leukaemia patients unresponsive to FLAG chemotherapy
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu